Interleukin 1-Pipeline Review H2 2018 – Healthcare Sector

Interleukin 1 (IL1)-Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of the brain that control body temperature. There are two forms of interleukin-1, alpha and beta. IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity.

Interleukin 1 (IL1) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 5, 1, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Cardiovascular, Oncology, Dermatology, Gastrointestinal, Metabolic Disorders, Musculoskeletal Disorders, Ear Nose Throat Disorders, Genetic Disorders, Central Nervous System, Genito Urinary System And Sex Hormones and Hematological Disorders which include indications Gouty Arthritis (Gout), Inflammation, Non-Small Cell Lung Cancer, Acne Vulgaris, Atopic Dermatitis (Atopic Eczema), Behcet Disease, Type 2 Diabetes, Arterial Thrombosis, Atherosclerosis, Autoimmune Disorders, Bullous Pemphigoid, Cancer Anorexia-Cachexia Syndrome, Cardiovascular Risk Factors, Cholangitis, Colorectal Cancer, Epidermolysis Bullosa, Esophageal Cancer, Fallopian Tube Cancer, Familial Mediterranean Fever, Hearing Disorders, Hidradenitis Suppurativa, Inflammatory Bowel Disease, Kidney Fibrosis, Limited/Distal Colitis, Liver Fibrosis, Lymphoma, Metastatic Colorectal Cancer, Muckle-Wells Syndrome, Myocardial Infarction, Neonatal Onset Multisystem Inflammatory Disease, Ovarian Cancer, Pain, Pancreatic Cancer, Pericarditis, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis, Restenosis, Rheumatoid Arthritis, Rhinitis, Sarcoidosis, Sickle Cell Disease, Skin Ulcers and Squamous Non-Small Cell Lung Cancer.

Download sample copy of this Report:


-The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1)
-The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects
-The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
-The report summarizes all the dormant and discontinued pipeline projects
-The report reviews latest news and deals related to Interleukin 1 (IL1) targeted therapeutics

Reasons to buy

-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Identify and understand the targeted therapy areas and indications for Interleukin 1 (IL1)
-Identify the use of drugs for target identification and drug repurposing
-Identify potential new clients or partners in the target demographic
-Develop strategic initiatives by understanding the focus areas of leading companies
-Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
-Devise corrective measures for pipeline projects by understanding Interleukin 1 (IL1) development landscape
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Get More Information about this Report:

Post Views:

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *